Table 1.

Existential literature including PBT patients in study design

Study	Study design	Overall sample	PBT sample	Domain assessed	Measure(s) used	Findings	PBT-specific results
Cho & Park (2017)	Cross-sectional	N = 292 • 91.8% White; 7.2% “Other” race • Age = 33.3 ± 7.1; range 18–47 • 80.5% female Years since   dx = 3.8 ± 2.8; range 0–16	N = 16 (5.5% of overall sample)	Fear of recurrence	Assessment of Survivor Concerns: Cancer Worry Subscale	• 49.1% Reported moderate-to-high or high fear of cancer recurrence • Fear of recurrence related to poorer physical and psychological QoL • Association between fear of recurrence and psychological QoL was moderated by perceived growth	None assessed
Cutshall et al. (2015)	Cross-sectional	N = 260 • 96.0% White, 1% Asian, 1 % Latino • Age = 64.6 ± 12.7; range not reported • 74.0% female • Years since dx presented categorically	N = 6 (2.3% of sample)	Fear of recurrence	Single item	• 52.0% of the sample reported fear of cancer recurrence represented “somewhat or more” of a bother • Fear of recurrence was the most prevalent endorsed concern	None assessed
Engelmann et al. (2016)	Cross-sectional	N = 77 • German (no further race/ethnicity reported) • Age = 57.5 ± 12.4; range 28–86 • 52.0% female • Years since   dx = 4.7 ± 4.0; range 1–19	N = 22 (28.6% of over all sample)	Death anxiety; fear of progression	DADDS (German version) Fear of Progression Questionnaire	• DADDS score = 13.3 ± 8.5 • Specific items associated with the most distress were feeling of being a burden to others, running out of time, and not knowing what happens near the end of life • Associated with depression, anxiety, fear of progression, and reduced QoL	None assessed
Goflaux et al. (2009)	Cross-sectional	N = 105 • Canadian (no further race/ethnicity reported) • Age = 47.4 ± 14.5; range not reported • 43.8% female • Years since dx not reported	N = 85 (81% of overall sample) • HG: 53.3% • LG: 16.2% • Met: 19.0% • Other: 11.4%	Fear of death	SNAS: a 30-item QoL measure developed by the authors; “symptom severity/fear of death” is one of 7 subscales	• Symptom severity/fear of death subscale not significantly associated with KPS, or treatment history (surgery, radiation, chemotherapy) • Those who were on AC Vs reported greater symptom severity/fear of death (P = . 03)	Sample size did not allow for analyses based on tumor characteristics
Langeveld et al. (2004)	Cross-sectional	N = 400 • Netherlands (no further race/ethnicity reported) • Age = 24.0 ± 4.9; range not reported • 45.0% female • Years since dx not reported	N = 43 (10.8% of sample)	Death concern; fear of recurrence	Worry Questionnaire with three subscales: cancer-specific concerns, general health concerns, present and future concerns	• Survivors reported significantly less worry about dying than healthy controls • 54.0% Reported worry about a cancer relapse • 50.0% Reported worry about having another cancer	None assessed
Muñoz et al. (2008)	Cross-sectional/mixed methods	N = 20 • 50.0% White, 5% Black, 15% Asian, 30% Latinx • Age = 45.8 (SD not reported); range 22.9–70.6 • 55.0% Female • Years since dx = 2.9 (SD not reported); range 0.3–7.4	N = 20 (100% of sample) • GBM: 35.0% • AA: 20.0% • Oligo: 15.0% • Other: 30.0%	Death anxiety, worry about condition worsening, fear of cancer spreading	Quality of Life—Cancer Survivor and FACT-Br (single items from validated measures)	• Worry about condition worsening was among the most negative concerns on the FACT-Br • Fear of cancer recurrence was among the most negative concerns on the QOLCS	None assessed
Tsai et al. (2005)	Longitudinal	N = 224 • Taiwanese (no further race/ethnicity reported) • Age = 62.1 ± 15.5; range not reported • 42.4% Female • Years since dx not reported	N = 3 (1.3% of overall sample)	Fear of death	Patient’s fear of death (scale of 1–5) was reported by members of the care team upon admission, 1 week after admission, and 2 days prior to death	• Older pts (> 65 years) reported greater fear of death 2 days before death; no age difference at earlier timepoints • Fear of death decreased throughout inpatient stay in both age groups	None assessed
Zebrack & Chesler (2002)	Cross-sectional	N = 175 • Race/ethnicity not reported • Age = 21.8 ± 3.3; range 16–28 • 57.4% Female • Years since   dx = 13.3 ± 5.7; range 3–27	N = 19 (10.9% of overall sample)	Fear of recurrence	Quality of Life—Cancer Survivor	• Most negatively rated concern in the psychological subscale was fear of cancer recurrence	None assessed

dx diagnosis, DADDS Death and Dying Distress Scale, QoL quality of life, HG high-grade tumor, LG low-grade tumor, Met metastasis, SNAS Sherbrooke Neuro-Oncology Assessment Scale, KPS Karnofsky Performance Status, ACV anticonvulsants, pts patients, SD standard deviation, GBM glioblastoma multiforme, AA anaplastic astrocytoma, Oligo oligodendroglioma, QOLCS Quality of Life—Cancer Survivor, FACT-Br Functional Assessment Cancer Therapy-Brain